Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 12/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 2/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29996099 | 1.00 | TLR8 (0.43) | TLR8ADORA2AADORA1KCNN4ATR | |
| SCHEMBL21063018 | 0.80 | KDM4E (0.45) | ADORA2AADORA1KDM4E | |
| SCHEMBL29996147 | 0.79 | ADORA2A (0.36) | ADORA2AADORA1GRM2 | |
| SCHEMBL21063335 | 0.79 | ADORA2A (0.36) | ADORA2AADORA1GRM2 | |
| SCHEMBL38657824 | 0.73 | GRM2 (0.48) | ADORA2AADORA1GRM2 | |
| SCHEMBL21063161 | 0.72 | ADORA2A (0.44) | TLR8ADORA2AADORA1KDM4E | |
| SCHEMBL29996830 | 0.72 | ADORA2A (0.44) | TLR8ADORA2AADORA1KDM4E | |
| SCHEMBL21063321 | 0.71 | ADORA1 (0.43) | TLR8ADORA2AADORA1 | |
| SCHEMBL21063210 | 0.70 | GRM5 (0.43) | KDM4E | |
| SCHEMBL21063123 | 0.70 | ADORA2A (0.47) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053973-A1 | IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2021-02-25 | — | — | US | claimed |
| EP-3723754-A1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2020-10-21 | — | — | EP | claimed |
| WO-2019118313-A1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2019-06-20 | — | — | WO | claimed |
| US-11498923-B2 | Substituted imidazo[1,2-c]quinazolines as A2A antagonists | MERCK SHARP & DOHME LLC (US) | 2022-11-15 | — | — | US | disclosed |
| US-11498923-B2 | Substituted imidazo[1,2-c]quinazolines as A2A antagonists | MERCK SHARP & DOHME LLC (US) | 2022-11-15 | — | — | US | disclosed |
| US-20210053973-A1 | IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210053973-A1 | IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2021-02-25 | — | — | US | disclosed |
| EP-3723754-A1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019118313-A1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019118313-A1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11498923-B2 | Substituted imidazo[1,2-c]quinazolines as A2A antagonists | ADORA2A, ADORA3, ADORA1 | TLR8 1644/4885ADORA2A 1/4885ADORA1 3/4885 |
| US-20210053973-A1 | IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | ADORA2A, ADORA3, ADORA1 | TLR8 1648/4885ADORA2A 1/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.